Baker Bros. Advisors 13F: New $7.2M Stake in EIKN

Baker Bros. Advisors Buys Into Eikon Therapeutics

Baker Bros. Advisors has established a brand-new stake in Eikon Therapeutics, Inc. (EIKN + NasdaqGS), according to the fund's latest Form 13F filing with the Securities and Exchange Commission. The prominent healthcare-focused investment firm purchased 555,555 shares of the clinical biopharmaceutical company. Based on the filing details, the transaction represents a total investment value of about $7.25 million, with an implied cost basis of $14.24 per share.

Known for its long-term, concentrated bets in the biotechnology sector, Baker Bros. Advisors often takes substantial positions in clinical-stage companies where it sees significant scientific promise. This new investment suggests the fund's management sees long-term value in Eikon's proprietary drug-discovery platform. Because Form 13F filings are backward-looking documents reflecting holdings at the end of the reporting period, they do not show the fund's active, real-time trading decisions.

Eikon Therapeutics Stock Trends

During Sunday trading, shares of Eikon Therapeutics closed at $13.05. The stock is currently trading in the upper half of its 52-week range, where it has fluctuated between a low of $7.90 and a high of $17.40. The current price represents a clear lift above the stock's 50-day moving average of $10.12, as well as its 200-day moving average of $11.01.

From a financial health perspective, Eikon Therapeutics maintains a current ratio of 9.89 and a quick ratio of 9.61. These liquidity metrics show the company has a strong buffer of short-term assets relative to its current liabilities. The firm's debt-to-equity ratio stands at 54.07, and it has a total market capitalization of approximately $478.28 million.

Recent Earnings and Financial Outlook

Eikon Therapeutics is a pre-revenue biotechnology business, which is typical for clinical-stage companies focusing all resources on research and development. In its most recent financial reports, the company reported an earnings per share (EPS) loss of $5.95, with a net margin of 0.0%. Because the company is not yet profitable, it does not have a meaningful price-to-earnings (P/E) ratio, though its forward P/E is listed at -1.39.

Investors looking for the company's next financial update can mark November 12, 2026, on their calendars, when Eikon Therapeutics is scheduled to report its next quarterly earnings results.

Analysts Set New Price Targets

Several research firms have weighed in on Eikon's market prospects with vastly different expectations. On October 16, 2026, HC Wainwright & Co. began covering the stock, assigning a Buy rating alongside a $23.00 price target. This bullish outlook contrasts sharply with a report from Wedbush on August 14, 2026, which maintained an Underperform rating on the stock and lowered its price target to $4.00 from a previous $5.00.

Across the five analyst opinions tracked by market researchers, the consensus recommendation for Eikon Therapeutics is a buy. The average price target stands at $24.60, with the most optimistic analyst projecting the stock to reach $32.00 and the most conservative forecasting a drop to $4.00.

Inside Eikon Therapeutics

Eikon Therapeutics is a clinical-stage biopharmaceutical firm dedicated to discovering and developing novel therapies for severe unmet medical needs. Under the leadership of CEO Dr. Roger M. Perlmutter, the company relies on advanced microscopy and machine learning to track the movement of proteins in living cells. Its current pipeline features several experimental therapies, including EIK1001 for anti-tumor immune responses, and selective PARP1 inhibitors designed to target breast, ovarian, and prostate cancers.

What's Ahead for Eikon Therapeutics, Inc.

For those watching Eikon Therapeutics, the key factors to monitor will be the clinical progression of its primary oncology candidates and its cash burn rate in upcoming quarters. While the backing of a specialized life sciences fund like Baker Bros. Advisors provides a notable vote of confidence, biotechnology investing remains highly volatile. Regulatory filings in the coming quarters will reveal whether Baker Bros. chooses to build upon this initial position or scale back its exposure.